Sumod-ong, Pedro .
HRN: 05-11-16 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/19/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
05/19/2022
05/25/2022
IV
600mg
Q8
Cutaneous Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes